Skip to main content

Talk Bio

Search This Blog

ASCO26: Revolution presents Phase III data that rewrites odds in pancreatic cancer

on June 01, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Revolution Medicines' RAS(ON) inhibitor daraxonrasib has produced unprecedented survival benefits in previously treated metastatic pancreatic cancer at ASCO26.

In the Phase III RASolute 302 trial, daraxonrasib doubled median overall survival (13.2 vs 6.7 months) and progression-free survival (7.2 vs 3.6 months) compared with standard second‑line chemotherapy.

The drug showed a 60% reduction in the risk of death (HR 0.40), worked regardless of RAS mutation status, had a manageable safety profile, and is being positioned as a new standard of care in second‑line metastatic pancreatic adenocarcinoma.

Sources:

ASCO26: Revolution's 'grand slam' data in pancreatic cancer

Pancreatic Cancer - The ASCO Post

Revolution Medicines Announces ASCO Plenary Presentation ...

Revolution Medicines starts early access for pancreatic cancer drug

RenovoRx To Announce Promising New Clinical Data Using its ...

First RAS Inhibitor Extends Survival in Previously Treated Metastatic ...

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 ...

Revolution Medicines to Present Pivotal Phase 3 RASolute ...

RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer

Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer

Rewinding 2025: A Year in Pancreatic Cancer Research

'Unprecedented' Revolution data point to paradigm shift in ...

May 10, 2026 - The ASCO Post

Revolution's RAS inhibitor hits key goals in ph. 3 cancer trial

ASCO 2026: Daraxonrasib doubles median overall survival ...

ASCO26 daraxonrasib Metastatic Pancreatic Ductal Adenocarcinoma oral targeted therapy Overall Survival Pancreatic Ductal Adenocarcinoma Revolution Medicines Secondary malignant neoplasm of pancreas Treating

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Powered by Blogger

X-Data LLC